We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Anticancer Therapies – Products

A labelled antibody and a cell.
Product News

FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Product News

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation To Support Scaling of Cell Therapy Manufacturing

Breakthrough medium delivers speed and scale to CAR-T cell therapy manufacturers.
Double helix structure of DNA.
Product News

University of Liverpool To Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical

The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.
Product News

Therapeutic Potential of CD20 X CD3 Bispecific Antibodies

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Cancer immunotherapy cells

Cancer Immunotherapies: The Paths From Models to Treatments

In this compendium, Technology Networks presents a collection of handpicked resources, including infographics, listicles, an article and webinar, that will help you to learn more about the latest advancements with disease modeling and cancer immunotherapies.
Someone holding a test tube next to a model of DNA.
Product News

N4 Pharma’s Novel Delivery Systems, Nuvec® and LipTide®, Advance Towards Commercialisation

N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.
Cell Therapy

Advances in Cell Therapy

This article examines recent advancements in cell therapy research, from promising lab findings poised for clinical translation to enhancements in development, testing, and manufacturing processes.
A healthcare worker tends to a patient receiving treatment in the hospital

Improving Cancer Patient Care With Professor Mark Lawler

In this article, Mark Lawler, professor of digital health, answers your questions about these revolutionary techniques and discusses the barriers to their implementation in the clinic. Prof. Lawler has an international reputation in cancer research and a focus on developing a molecular understanding of cancer to improve patient care, including through precision medicine.
White laboratory mouse sitting on top of test tubes

Advanced Oncology Treatment Candidates Developed With Next-Generation Preclinical Models

One factor that can significantly impact the success of oncology drug development is the preclinical model used. The right model can provide valuable insights into key interactions within the body and help researchers to better understand how tumors respond to treatment.
Novel CAR Technology To Transform Cancer Therapy

Novel CAR Technology To Transform Cancer Therapy

Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.